semaglutide shortage news november 2025 Market Size, Share & Trends Report, 2025-2035 US judge upholds FDA's removal

Eli Lillys Direct-to-Employer Platform On March 5, 2026, Eli Lilly officially launched Lilly Employer Connect, a program giving employers a direct route to offer Zepbound to their employees at the $449 direct-to-employer price, completely outside the traditional insurance and PBM channel

Clinical Evidence for Semaglutide-Naltrexone Combination The strongest evidence for semaglutide plus naltrexone comes from the IMCOSI phase 2b trial (2021), which enrolled 338 patients and found that the combination resulted in approximately 20% body weight loss over 48 weeks, compared to 16% for semaglutide alonea difference that was statistically significant but modest in absolute terms

Package Included: SHOWER GEL (500ml)

Potential for improved adherence Patients taking transdermal patches have exhibited better adherence compared to other administration routes